In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Rocket Pharmaceuticals Inc (NASDAQ: RCKT) closed at $17.19 in the last session, up 2.20% from day before closing price of $16.82. In other words, the price has increased by $2.20 from its previous closing price. On the day, 0.97 million shares were traded. RCKT stock price reached its highest trading level at $17.21 during the session, while it also had its lowest trading level at $16.12.
Ratios:
We take a closer look at RCKT’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 7.79 and its Current Ratio is at 7.79. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
On April 02, 2024, Goldman started tracking the stock assigning a Neutral rating and target price of $39.
On October 24, 2023, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $65.Cantor Fitzgerald initiated its Overweight rating on October 24, 2023, with a $65 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 31 ’24 when White Mark Andrew sold 3,080 shares for $16.62 per share. The transaction valued at 51,205 led to the insider holds 69,140 shares of the business.
Militello John sold 917 shares of RCKT for $15,245 on Oct 31 ’24. The insider now owns 50,534 shares after completing the transaction at $16.62 per share. On Oct 31 ’24, another insider, Militello John, who serves as the Officer of the company, bought 917 shares for $16.62 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RCKT now has a Market Capitalization of 1563875840 and an Enterprise Value of 1310848000.
Stock Price History:
Over the past 52 weeks, RCKT has reached a high of $32.53, while it has fallen to a 52-week low of $15.98. The 50-Day Moving Average of the stock is -5.12%, while the 200-Day Moving Average is calculated to be -24.28%.
Shares Statistics:
According to the various share statistics, RCKT traded on average about 829.67K shares per day over the past 3-months and 586060 shares per day over the past 10 days. A total of 90.28M shares are outstanding, with a floating share count of 83.82M. Insiders hold about 7.87% of the company’s shares, while institutions hold 98.46% stake in the company. Shares short for RCKT as of 1728950400 were 11515890 with a Short Ratio of 13.88, compared to 1726185600 on 11262034. Therefore, it implies a Short% of Shares Outstanding of 11515890 and a Short% of Float of 26.87.
Earnings Estimates
The performance of Rocket Pharmaceuticals Inc (RCKT) in the stock market is under the watchful eye of 15.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.71, with high estimates of $0.24 and low estimates of -$0.9.
Analysts are recommending an EPS of between -$1.59 and -$3.12 for the fiscal current year, implying an average EPS of -$2.84. EPS for the following year is -$2.6, with 15.0 analysts recommending between -$1.51 and -$3.21.
Revenue Estimates
Based on 11 analysts’ estimates, the company’s revenue will be $64.26M in the next fiscal year. The high estimate is $117.96M and the low estimate is $5M.
